Patents Assigned to Orexo AB
-
Patent number: 8454996Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: GrantFiled: November 22, 2011Date of Patent: June 4, 2013Assignee: Orexo ABInventors: Anders Pettersson, Christer Nystrom
-
Publication number: 20130071477Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.Type: ApplicationFiled: September 18, 2012Publication date: March 21, 2013Applicant: Orexo ABInventor: Orexo AB
-
Publication number: 20130017263Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.Type: ApplicationFiled: September 17, 2012Publication date: January 17, 2013Applicant: OREXO ABInventors: ANDERS PETTERSSON, CHRISTER NYSTROM, YVONNE HAKANSSON
-
Publication number: 20120315330Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: ApplicationFiled: November 22, 2011Publication date: December 13, 2012Applicant: OREXO ABInventors: ANDERS PETTERSSON, CHRISTER NYSTROM
-
Publication number: 20120315331Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: ApplicationFiled: November 22, 2011Publication date: December 13, 2012Applicant: OREXO ABInventors: Anders Pettersson, Christer Nystrom
-
Publication number: 20120277261Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: ApplicationFiled: February 22, 2012Publication date: November 1, 2012Applicant: Orexo ABInventors: Anders Pettersson, Christer Nystrom, Susanne Bredenberg
-
Publication number: 20120121664Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage for in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.Type: ApplicationFiled: January 23, 2012Publication date: May 17, 2012Applicant: OREXO ABInventors: Anders Pettersson, Christer Nyström, Yvonne Hakansson
-
Publication number: 20120015007Abstract: There is provided a sustained-release pharmaceutical composition comprising a solid, continuous network comprising an excipient with a high mechanical strength, which network also comprises pores, within which pores is interspersed a mixture of an active ingredient and a film-forming agent, characterised in that said pores are formed during the production of the composition. Compositions of the invention find particularly utility as abuse-resistant formulations comprising opioid analgesics that may be employed in the treatment of chronic pain.Type: ApplicationFiled: March 2, 2010Publication date: January 19, 2012Applicant: OREXO ABInventors: Susanne Bredenberg, Anne Dahlgren, Anders Sagstrom, Hakan Engqvist
-
Publication number: 20110268796Abstract: There is provided a formulation suitable for transmucosal administration comprising a short acting hypnotic drug, which formulation provides a measurable plasma concentration of drug within 10 minutes of administration. The formulation is capable of providing sleep on demand, and preferably comprises particles of drug, for example zolpidem or a pharmaceutically-acceptable salt thereof and a mucoadhesion promoting agent, such as sodium carboxymethylcellulose, which particles of drug and mucoadhesive are presented upon the surface of larger carrier particles.Type: ApplicationFiled: July 15, 2011Publication date: November 3, 2011Applicant: OREXO ABInventors: Anders Pettersson, Christer Nyström, Susanne Bredenberg
-
Publication number: 20110256229Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially insoluble or sparingly soluble in water, in combination with a bioadhesion and/or mucoadhesion promoting agent adhered to the surfaces of said carrier particles. The composition is primarily intended for sublingual or intranasal administration. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: ApplicationFiled: June 30, 2011Publication date: October 20, 2011Applicant: OREXO ABInventors: CHRISTER NYSTROM, SASANNE BREDENBERG
-
Patent number: 7910132Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: GrantFiled: October 10, 2006Date of Patent: March 22, 2011Assignee: Orexo ABInventors: Anders Pettersson, Christer Nystrom
-
Patent number: 7815940Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid susceptible proton pump inhibitor or a salt thereof, an H2 receptor antagonist or a salt thereof and a pharmaceutically acceptable carrier. The dosage form is capable of raising gastric pH to above 4 within two hours after administration and to keep it at that level for at least 4 hours. Also disclosed is a method of manufacture of the dosage form, its use in treating dyspepsia and infection by Helicobacter pylori, and a method of treating disorders associated with gastric acid secretion.Type: GrantFiled: April 17, 2002Date of Patent: October 19, 2010Assignee: Orexo ABInventor: Anders Pettersson
-
Patent number: 7785626Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.Type: GrantFiled: October 15, 2003Date of Patent: August 31, 2010Assignee: OREXO ABInventors: Anders Pettersson, Christer Nyström, Yvonne Håkansson
-
Patent number: 7771747Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.Type: GrantFiled: October 10, 2006Date of Patent: August 10, 2010Assignee: Orexo ABInventors: Anders Pettersson, Christer Nyström, Yvonne Håkansson
-
Publication number: 20080286368Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: ApplicationFiled: July 1, 2008Publication date: November 20, 2008Applicant: Orexo ABInventors: Anders Pettersson, Christer Nystrom
-
Publication number: 20070031497Abstract: An oral pharmaceutical dosage form comprises pharmacologically effective amounts of an acid-susceptible proton pump inhibitor and an H2 receptor antagonist in combination with at least on pharmacologically acceptable excipient which causes a delayed release and/or an extended release of the proton pump inhibitor. The H2 receptor antagonist is included in the dosage form in such a way that it is rapidly released after administration. This dosage form is suitable for the treatment of conditions associated with an excessive secretion of gastric acid and provides a suitable combination of a rapid onset and a long-lasting duration of the effect. The invention also relates to a method for manufacturing such a dosage form and to a method for the treatment of conditions associated with the secretion of gastric acid.Type: ApplicationFiled: October 10, 2006Publication date: February 8, 2007Applicant: OREXO ABInventors: Anders Pettersson, Christer Nystrom, Yvonne Hakansson
-
Publication number: 20060216352Abstract: A pharmaceutical composition for the treatment of acute disorders is described. The composition includes an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially insoluble or sparingly soluble in water, in combination with a bioadhesion and/or mucoadhesion promoting agent adhered to the surfaces of the carrier particles. The composition is primarily intended for sublingual or intranasal administration. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.Type: ApplicationFiled: January 15, 2004Publication date: September 28, 2006Applicant: OREXO ABInventors: Christer Nystrom, Susanne Bredenberg
-
Patent number: 6962687Abstract: A method of detecting inflammatory processes comprises (a) administering per-orally or per-rectally a composition comprising a diagnostically effective amount of L-[guanido-15N2]-arginine, L-[guanido-15N]-arginine, their mixtures and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier; (b) collecting a sample of exhaled air, saliva or urine; (c) determining 13NO in the air sample or its transformation products 15IN-nitrite and/or 15N-nitrate in the saliva sample or urine. Also disclosed is a corresponding diagnostic composition for use in diagnosing inflammatory processes and a method for its manufacture.Type: GrantFiled: October 24, 2000Date of Patent: November 8, 2005Assignee: Orexo ABInventors: Anders Pettersson, Thomas Lundqvist